Bio Green Med Solution Inc (BGMSP) Financial

Bio Green Med Solution, Inc. is a clinical stage biopharmaceutical company, which engages in the provision of cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company develops medicines based on cell cycle, epigenetics and mitosis biology. Its Polo-like kinase 1 (PLK1) is a serine/threonine kinase with a central role in cell division and an important regulator of the DNA damage checkpoint. PLK1 overexpression correlates with poor patient prognosis in several tumors, including esophageal, gastric, leukemia, non-small cell lung cancer, ovarian, and squamous cell cancers, as well as MYC-amplified cancers. Plogosertib is a novel, small molecule, selective and potent PLK1 inhibitor. Its Fire Safety division specializes in supplying and trading various protective and fire safety equipment to both domestic and international markets. The company provides fire safety products, including fire extinguishers, foam systems, fire-resistant doors, personal protective equipment, and fire safety apparel.